Rapid Injection Technique Improves Production of Genetically Engineered Mice
|
By LabMedica International staff writers Posted on 06 Jun 2016 |

Image: Electroporation jolts embryos with electricity to open holes that allow the CRISPR-Cas9 molecule (lower right) to enter and edit the DNA (Photo courtesy of Dr. Andrew Modzelewski, Dr. Lin He, University of California, Berkeley).
An electroporation method has been introduced that improves the production of genetically altered "knock-out" mice by requiring less time and being more efficient at introducing the CRISPR-Cas9 genome editing complex than is the current microinjection method.
CRISPRs (clustered regularly interspaced short palindromic repeats) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacterial virus or plasmid. CRISPRs are found in approximately 40% of sequenced bacteria genomes and 90% of sequenced archaea. CRISPRs are often associated with cas genes that code for proteins related to CRISPRs. The CRISPR/Cas complex comprises a prokaryotic immune system that confers resistance to foreign genetic elements such as plasmids and phages and provides a form of acquired immunity. Since 2013, the CRISPR/Cas system has been used in research for gene editing (adding, disrupting, or changing the sequence of specific genes) and gene regulation. By delivering the Cas9 protein and appropriate guide RNAs into a cell, the organism's genome can be cut at any desired location. The conventional CRISPR-Cas9 system is composed of two parts: the Cas9 enzyme, which cleaves the DNA molecule and specific RNA guides (CRISPRs) that shepherd the Cas9 protein to the target gene on a DNA strand.
CRISPR-mediated mouse genome editing is typically accomplished by microinjection of Cas9 DNA/RNA and single-guide RNA into zygotes to generate modified animals in one step. However, microinjection is a technically demanding, labor-intensive, and costly procedure with poor embryo viability. In practice, the microinjection method requires inoculation of individual cells or embryos with two RNA molecules - messenger RNA (mRNA), which codes for the Cas9 protein, and guide RNA, which provides the address for CRISPR-Cas9's target. In only a small percentage of cells the mRNA is properly translated into Cas9 protein, and the protein correctly combines with the guide RNA.
Electroporation relies on a burst of electricity to create holes in cells or embryos through which molecules can enter. Investigators at the University of California, Berkeley (USA) recently described a novel adaptation of the technique, which they called CRISPR-EZ (CRISPR RNP Electroporation of Zygotes). They described this simple and cost-effective methodology, which can be performed on many embryos at once and takes only milliseconds to perform in the May 5, 2016, online edition of the Journal of Biological Chemistry.
Using CRISPR-EZ, which could deliver Cas9/sgRNA ribonucleoproteins (RNPs) into mouse zygotes with 100% efficiency, the investigators generated a variety of editing schemes in mouse embryos, including indel (insertion/deletion) mutations, point mutations, large deletions, and small insertions. In a proof-of-principle experiment, they used CRISPR-EZ to target the Tyrosinase (Tyr) gene, achieving 88% bi-allelic editing and 42% Homology-Directed Repair (HDR)-mediated precise sequence modification in live mice.
"The key fundamental insights about the biological significance of a gene usually come from in vivo gene-editing studies, in which you generate mice with an altered gene," said senior author Dr. Lin He, a associate professor of molecular and cell biology at the University of California, Berkeley. "But it is a major commitment to make a novel knockout with genome engineering. I think this technology could greatly reduce the technical barrier for this type of effort and will allow people to focus more on the science rather than be consumed by the process of genetically engineering mice."
"The actual percentage of live births from injected embryos is around 10 to 15% for most transgenic facilities, which is a problem with the procedure," said Dr. He. "Sometimes people collect more than 100 embryos just to generate one or two mice with desirable gene editing. Electroporation appears to do less damage to the embryos than microinjection: between 30% and 50% of the embryos resulted in live births."
Related Links:
University of California, Berkeley
CRISPRs (clustered regularly interspaced short palindromic repeats) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacterial virus or plasmid. CRISPRs are found in approximately 40% of sequenced bacteria genomes and 90% of sequenced archaea. CRISPRs are often associated with cas genes that code for proteins related to CRISPRs. The CRISPR/Cas complex comprises a prokaryotic immune system that confers resistance to foreign genetic elements such as plasmids and phages and provides a form of acquired immunity. Since 2013, the CRISPR/Cas system has been used in research for gene editing (adding, disrupting, or changing the sequence of specific genes) and gene regulation. By delivering the Cas9 protein and appropriate guide RNAs into a cell, the organism's genome can be cut at any desired location. The conventional CRISPR-Cas9 system is composed of two parts: the Cas9 enzyme, which cleaves the DNA molecule and specific RNA guides (CRISPRs) that shepherd the Cas9 protein to the target gene on a DNA strand.
CRISPR-mediated mouse genome editing is typically accomplished by microinjection of Cas9 DNA/RNA and single-guide RNA into zygotes to generate modified animals in one step. However, microinjection is a technically demanding, labor-intensive, and costly procedure with poor embryo viability. In practice, the microinjection method requires inoculation of individual cells or embryos with two RNA molecules - messenger RNA (mRNA), which codes for the Cas9 protein, and guide RNA, which provides the address for CRISPR-Cas9's target. In only a small percentage of cells the mRNA is properly translated into Cas9 protein, and the protein correctly combines with the guide RNA.
Electroporation relies on a burst of electricity to create holes in cells or embryos through which molecules can enter. Investigators at the University of California, Berkeley (USA) recently described a novel adaptation of the technique, which they called CRISPR-EZ (CRISPR RNP Electroporation of Zygotes). They described this simple and cost-effective methodology, which can be performed on many embryos at once and takes only milliseconds to perform in the May 5, 2016, online edition of the Journal of Biological Chemistry.
Using CRISPR-EZ, which could deliver Cas9/sgRNA ribonucleoproteins (RNPs) into mouse zygotes with 100% efficiency, the investigators generated a variety of editing schemes in mouse embryos, including indel (insertion/deletion) mutations, point mutations, large deletions, and small insertions. In a proof-of-principle experiment, they used CRISPR-EZ to target the Tyrosinase (Tyr) gene, achieving 88% bi-allelic editing and 42% Homology-Directed Repair (HDR)-mediated precise sequence modification in live mice.
"The key fundamental insights about the biological significance of a gene usually come from in vivo gene-editing studies, in which you generate mice with an altered gene," said senior author Dr. Lin He, a associate professor of molecular and cell biology at the University of California, Berkeley. "But it is a major commitment to make a novel knockout with genome engineering. I think this technology could greatly reduce the technical barrier for this type of effort and will allow people to focus more on the science rather than be consumed by the process of genetically engineering mice."
"The actual percentage of live births from injected embryos is around 10 to 15% for most transgenic facilities, which is a problem with the procedure," said Dr. He. "Sometimes people collect more than 100 embryos just to generate one or two mice with desirable gene editing. Electroporation appears to do less damage to the embryos than microinjection: between 30% and 50% of the embryos resulted in live births."
Related Links:
University of California, Berkeley
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples
Channels
Clinical Chemistry
view channel
VOCs Show Promise for Early Multi-Cancer Detection
Early cancer detection is critical to improving survival rates, but most current screening methods focus on individual cancer types and often involve invasive procedures. This makes it difficult to identify... Read more
Portable Raman Spectroscopy Offers Cost-Effective Kidney Disease Diagnosis at POC
Kidney disease is typically diagnosed through blood or urine tests, often when patients present with symptoms such as blood in urine, shortness of breath, or weight loss. While these tests are common,... Read moreMolecular Diagnostics
view channel
Urine Test Detects Early Stage Pancreatic Cancer
Pancreatic cancer remains among the hardest cancers to detect early. In the UK, around 10,000 people are diagnosed each year, but only 5% survive beyond five years. Late diagnosis is a major factor—more... Read more
Genomic Test Could Reduce Lymph Node Biopsy Surgery in Melanoma Patients
Accurately determining whether melanoma has spread to the lymph nodes is crucial for guiding treatment decisions, yet the standard procedure—sentinel lymph node biopsy—remains invasive, costly, and unnecessary... Read moreHematology
view channel
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read more
Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage
Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more
Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read moreImmunology
view channel
Blood-Based Liquid Biopsy Model Analyzes Immunotherapy Effectiveness
Immunotherapy has revolutionized cancer care by harnessing the immune system to fight tumors, yet predicting who will benefit remains a major challenge. Many patients undergo costly and taxing treatment... Read more
Signature Genes Predict T-Cell Expansion in Cancer Immunotherapy
Modern cancer immunotherapies rely on the ability of CD8⁺ T cells to rapidly multiply within tumors, generating the immune force needed to eliminate cancer cells. However, the biological triggers behind... Read moreMicrobiology
view channel
Fast Noninvasive Bedside Test Uses Sugar Fingerprint to Detect Fungal Infections
Candida bloodstream infections are a growing global health threat, causing an estimated 6 million cases and 3.8 million deaths annually. Hospitals are particularly vulnerable, as weakened patients after... Read more
Rapid Sepsis Diagnostic Device to Enable Personalized Critical Care for ICU Patients
Sepsis is a life-threatening condition that occurs when the body’s response to infection spirals out of control, damaging organs and leading to critical illness. Patients often arrive at intensive care... Read morePathology
view channel
New Molecular Analysis Tool to Improve Disease Diagnosis
Accurately distinguishing between similar biomolecules such as proteins is vital for biomedical research and diagnostics, yet existing analytical tools often fail to detect subtle structural or compositional... Read more
Tears Offer Noninvasive Alternative for Diagnosing Neurodegenerative Diseases
Diagnosing and monitoring eye and neurodegenerative diseases often requires invasive procedures to access ocular fluids. Ocular fluids like aqueous humor and vitreous humor contain valuable molecular information... Read moreTechnology
view channel
Cell-Sorting Device Uses Electromagnetic Levitation to Precisely Direct Cell Movement
Sorting different cell types—such as cancerous versus healthy or live versus dead cells—is a critical task in biology and medicine. However, conventional methods often require labeling, chemical exposure,... Read more
Embedded GPU Platform Enables Rapid Blood Profiling for POC Diagnostics
Blood tests remain a cornerstone of medical diagnostics, but traditional imaging and analysis methods can be slow, costly, and reliant on dyes or contrast agents. Now, scientists have developed a real-time,... Read moreIndustry
view channel
Qiagen Acquires Single-Cell Omics Firm Parse Biosciences
QIAGEN (Venlo, Netherlands) has entered into a definitive agreement to fully acquire Parse Biosciences (Seattle, WA, USA), a provider of scalable, instrument-free solutions for single-cell research.... Read more
Puritan Medical Products Showcasing Innovation at AMP2025 in Boston
Puritan Medical Products (Guilford, ME, USA), the world’s most trusted manufacturer of swabs and specimen collection devices, is set to exhibit at AMP2025 in Boston, Massachusetts, from November 11–15.... Read more
Advanced Instruments Merged Under Nova Biomedical Name
Advanced Instruments (Norwood, MA, USA) and Nova Biomedical (Waltham, MA, USA) are now officially doing business under a single, unified brand. This transformation is expected to deliver greater value... Read more








